Caplin Point Laboratories Limited

BSE:524742 Stock Report

Market Cap: ₹165.5b

Caplin Point Laboratories Past Earnings Performance

Past criteria checks 3/6

Caplin Point Laboratories has been growing earnings at an average annual rate of 19%, while the Pharmaceuticals industry saw earnings growing at 13.6% annually. Revenues have been growing at an average rate of 16.3% per year. Caplin Point Laboratories's return on equity is 19.3%, and it has net margins of 26.9%.

Key information

19.0%

Earnings growth rate

19.0%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate16.3%
Return on equity19.3%
Net Margin26.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Caplin Point Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:524742 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2418,3284,9361,580737
30 Jun 2417,5774,7761,4870
31 Mar 2416,9614,5711,437737
31 Dec 2316,3184,3761,430632
30 Sep 2315,6834,1791,408632
30 Jun 2315,1573,9471,3960
31 Mar 2314,6833,7631,371632
31 Dec 2214,1823,5321,314593
30 Sep 2213,7243,3071,262593
30 Jun 2213,1533,1401,2100
31 Mar 2212,7102,9981,154593
31 Dec 2112,0992,8721,110537
30 Sep 2111,5812,7671,071537
30 Jun 2111,2172,5861,0340
31 Mar 2110,6242,4231,026537
31 Dec 209,9862,248952530
30 Sep 209,5242,189874530
30 Jun 209,1072,1937800
31 Mar 208,6402,150678530
31 Dec 198,3562,159617282
30 Sep 197,6642,032557282
30 Jun 196,9481,8945120
31 Mar 196,4901,766471282
31 Dec 186,0481,621449237
30 Sep 185,8741,538431237
30 Jun 185,6281,4594170
31 Mar 185,3991,448391237
31 Dec 175,1451,430367141
30 Sep 174,7571,297352141
30 Jun 174,4011,1653220
31 Mar 174,016956321141
31 Dec 163,65578330054
30 Sep 163,42070327454
30 Jun 163,23861925854
31 Mar 163,08858424054
31 Dec 152,90653529867
30 Sep 152,72246528360
30 Jun 152,51841020359
31 Mar 152,29635323353
31 Dec 142,07431822042
30 Sep 141,89330520433
30 Jun 141,73125819021
31 Mar 141,6432041664

Quality Earnings: 524742 has high quality earnings.

Growing Profit Margin: 524742's current net profit margins (26.9%) are higher than last year (26.6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 524742's earnings have grown by 19% per year over the past 5 years.

Accelerating Growth: 524742's earnings growth over the past year (18.1%) is below its 5-year average (19% per year).

Earnings vs Industry: 524742 earnings growth over the past year (18.1%) did not outperform the Pharmaceuticals industry 20.6%.

Return on Equity

High ROE: 524742's Return on Equity (19.3%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/22 21:14
End of Day Share Price 2025/01/22 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Caplin Point Laboratories Limited is covered by 2 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Rohit BhatBatlivala & Karani Securities India Pvt. Ltd.
Siddhant KhandekarICICIdirect.com